Loading...

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

BACKGROUND: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may nee...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Exp Hematol Oncol
Main Authors: Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z., Naing, Aung, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171918/
https://ncbi.nlm.nih.gov/pubmed/32337094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00159-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!